Zhang, B., Zhong, R., Shi, C., Chu, T., Zhang, W., Wang, H., Gan, X., Zhang, Z., Zhu, C., Li, X., Su, W., Li, J., Zhang, Y., Han, B., Zhong, H. (2026). Durvalumab plus anlotinib versus durvalumab alone as maintenance treatment in extensive-stage small-cell lung cancer (DURABLE): a multicenter, randomized, phase II trial and biomarker analysis. Nature Communications. https://doi.org/10.1038/s41467-026-73562-7